Indoramin as an antihypertensive agent in the treatment of essential hypertension. A multicentre trial.
The efficacy of indoramin (Baratol; Wyeth) in combination with a thiazide diuretic was assessed in an open non-comparative trial. The dosage of indoramin was increased at 2-weekly intervals until control was obtained or until a maximum daily dosage of 150 mg was reached. Treatment was successful in 78% of patients and a significant reduction in diastolic blood pressure (DBP) was obtained in another 7%. In combination with a thiazide diuretic, indoramin, when individually titrated for each patient, reduced the DBP by an average of 20 mmHg. When taken with a thiazide diuretic, indoramin 75 mg/d or less controlled the DBP in 76% of all the patients. The effect of indoramin on the pulse rate was minimal. For all practical purposes, orthostatic hypotension did not occur. A number of patients presented with side-effects but these proved to be transient in a large percentage of cases.
D001581:Benzothiadiazines; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D003971:Diastole; D004232:Diuretics; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007211:Indoles / Q000008:administration & dosage*; D007217:Indoramin / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D049993:Sodium Chloride Symporter Inhibitors / Q000008:administration & dosage
D001581:Benzothiadiazines; D004232:Diuretics; D007211:Indoles; D049993:Sodium Chloride Symporter Inhibitors; D007217:Indoramin